TradeLink Capital LLC Acquires New Position in Zoetis Inc (ZTS)

Share on StockTwits

TradeLink Capital LLC acquired a new position in Zoetis Inc (NYSE:ZTS) in the second quarter, Holdings Channel reports. The fund acquired 2,900 shares of the company’s stock, valued at approximately $247,000. Zoetis makes up approximately 1.2% of TradeLink Capital LLC’s investment portfolio, making the stock its 21st biggest position.

Other large investors have also modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in Zoetis by 8.7% in the second quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock worth $448,309,000 after purchasing an additional 422,856 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Zoetis by 50.7% in the second quarter. Teacher Retirement System of Texas now owns 381,617 shares of the company’s stock worth $32,510,000 after purchasing an additional 128,448 shares during the last quarter. Sivik Global Healthcare LLC grew its holdings in Zoetis by 37.5% in the second quarter. Sivik Global Healthcare LLC now owns 55,000 shares of the company’s stock worth $4,685,000 after purchasing an additional 15,000 shares during the last quarter. Signition LP purchased a new position in Zoetis in the second quarter worth $372,000. Finally, Navellier & Associates Inc grew its holdings in Zoetis by 126.4% in the second quarter. Navellier & Associates Inc now owns 50,730 shares of the company’s stock worth $4,322,000 after purchasing an additional 28,327 shares during the last quarter. 90.45% of the stock is owned by institutional investors.

ZTS has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $98.00 price target on shares of Zoetis in a report on Wednesday, May 16th. Craig Hallum reaffirmed a “buy” rating and issued a $94.00 price target (up from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. Bank of America lifted their price target on shares of Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 30th. Jefferies Financial Group set a $96.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, July 13th. Finally, Citigroup reissued a “buy” rating and set a $98.00 price objective (up from $85.00) on shares of Zoetis in a report on Thursday, April 19th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and an average price target of $89.64.

In related news, insider Kristin C. Peck sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total transaction of $431,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roman Trawicki sold 8,266 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $92.53, for a total transaction of $764,852.98. The disclosure for this sale can be found here. Insiders have sold 15,283 shares of company stock valued at $1,366,924 over the last 90 days. 0.35% of the stock is currently owned by insiders.

Shares of ZTS opened at $91.70 on Friday. The firm has a market cap of $44.52 billion, a PE ratio of 32.31, a P/E/G ratio of 1.90 and a beta of 1.02. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38. Zoetis Inc has a 1-year low of $59.64 and a 1-year high of $93.67.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.53 earnings per share. sell-side analysts anticipate that Zoetis Inc will post 3.07 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: Earnings Per Share

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply